Products
BioDigit Database™
Digital, clinical, and biological research data for endpoint development.
BioDigit Database brings together data from BioSensics research to study daily function, explore candidate endpoints, and connect digital measures with clinical outcomes. Depending on the cohort, data include repeated at-home recordings, structured assessments, and selected biological measures.
Digital measures with clinical context
Explore how movement, speech, cognition, and daily function relate to clinical assessments, participant experience, and selected biological measures.
Research cohorts and study enrollment
Explore the research supporting BioDigit Database across 14 indications, including completed studies, ongoing collection, and planned cohorts. Study enrollment provides context; it does not by itself establish the number of records available for a new analysis.
14 indications
| Indication | Participants / enrollment | Collection / follow-up | Data and study context |
|---|---|---|---|
| Alzheimer’s disease and related cognitive impairment Neurodegenerative Research details: Alzheimer’s disease and related cognitive impairment |
494 actual participant enrollments across five studies 100 estimated in one planned study |
48 hours–12 months Recording and follow-up periods vary by protocol. |
Cognition, daily function, activity, care coordination, and remotely supervised exercise.
Includes cognitive impairment, controls, aging/frailty participants, and caregivers; this is not an AD-only patient count. |
| Amyotrophic lateral sclerosis Neuromuscular Research details: Amyotrophic lateral sclerosis |
62 actual enrollments across two studies |
Single visit / 12 months Two distinct study designs. |
Wearable movement, digital functional assessments, and clinical outcomes in motor neuron disease.
Includes eligible ALS, PLS, and PMA participants and healthy controls. The diagnostic split is not reported. |
| Corticobasal syndrome Neurodegenerative Research details: Corticobasal syndrome |
20 estimated across one shared FTLD study |
12 months Planned visits every three months. |
Daily activity, gait, speech, cognitive and fine motor tasks, and guided video assessments.
The same 20-person protocol is listed under FTD. CBS enrollment is not separately specified. |
| Charcot-Marie-Tooth disease Neuromuscular Research details: Charcot-Marie-Tooth disease |
48 actual · completed study 100 estimated · upcoming study |
Up to 2 years Reported BioDigit cohort; published home recordings cover 14 days. | Gait, balance, daily activity, upper-limb movement, and clinical function. |
| Dementia with Lewy bodies Neurodegenerative Research details: Dementia with Lewy bodies |
30 estimated DLB / MCI-LB participants |
14 days Planned home recording after baseline assessments. |
Activity, gait, upper-limb movement, speech, cognition, and clinical assessments.
One 60-person study plans 30 PSP and 30 DLB or MCI with Lewy bodies participants. |
| Duchenne muscular dystrophy Neuromuscular Research details: Duchenne muscular dystrophy |
54 estimated · 2 ongoing studies |
Not specified Research program described. | Wearable measures of daily movement and early motor development. |
| Friedreich ataxia Neuromuscular Research details: Friedreich ataxia |
58 actual · completed study |
24 months Reported wearable follow-up; published analysis uses seven days. | Wearable movement, clinical severity scores, and selected biological measures. |
| Frontotemporal dementia Neurodegenerative Research details: Frontotemporal dementia |
20 estimated across one shared FTLD study |
12 months Planned visits every three months. |
Activity, gait, speech, cognitive and fine motor tasks, and oculomotor assessments.
The same 20-person protocol is listed under CBS. FTD enrollment is not separately specified. |
| Huntington disease Neurodegenerative Research details: Huntington disease |
44 participants reported by BioSensics 125 estimated registry enrollments: 50 + 75 |
Up to 2.5 years Reported HD cohort; HD-02 plans 12 months. |
Clinical assessments, digital tasks, and scheduled wearable recordings.
The original registry still lists 50 estimated and an unknown status. BioSensics separately reports a completed 44-person cohort. |
| Inclusion body myositis Autoimmune Research details: Inclusion body myositis |
20 estimated enrollment |
12 months Registry assessments at baseline, month 6, and month 12. |
Mobility, upper-limb movement, clinical strength and function, and participant reports.
Active, not recruiting. The research page describes longer monitoring; the registry specifies 12-month assessments. |
| Myasthenia gravis Autoimmune Research details: Myasthenia gravis |
20 participants reported in the initial study 95 estimated registry enrollments: 20 + 50 + 25 |
Study-specific Includes longitudinal monitoring and two treatment cycles. |
Speech, ocular video, activity, respiratory assessments, and participant-reported outcomes.
The initial 20-person cohort is described in publications and the MG2 record. Registry enrollment fields remain estimated; the cohort is not added again. |
| Parkinson’s disease Neurodegenerative Research details: Parkinson’s disease |
20 actual · completed study |
Study-specific Clinical visits, short recordings, and task assessments. | Gait, balance, activity, speech, and cognitive-motor performance. |
| Progressive supranuclear palsy Neurodegenerative Research details: Progressive supranuclear palsy |
48 actual · completed studies 280 estimated · two upcoming studies |
14 days–12 months Recording and follow-up vary by study. | Speech, mobility, falls, upper-limb movement, cognitive tasks, and clinical outcomes. |
| Spinocerebellar ataxia Neuromuscular Research details: Spinocerebellar ataxia |
18 actual · completed study 25 estimated · one upcoming study |
Single visit / 12 months Completed assessments and planned follow-up. | Gait, balance, and upper-limb measures; planned remote assessments and optional baseline blood sampling. |
Actual enrollment, estimated study targets, and company-reported or published samples are labeled separately. Counts can include controls, related diagnoses, or caregivers. Shared studies and overlapping analyses are not added into a database-wide total. Available data, completed assessments, and permitted use are confirmed for each project.
Complementary data across research cohorts
The selected cohort determines which recordings, assessments, and outcomes can be analyzed together. The research portfolio includes these complementary data domains.
-
Activity, mobility, and falls
Wearable recordings of movement, walking, posture, and transitions, with fall-related measures and structured gait or balance assessments in selected studies.
-
Upper-limb and fine motor function
Daily-life upper-limb recordings and structured movement, tracing, or other fine motor tasks to characterize functional performance.
-
Speech and cognition
Standardized speech recordings, verbal fluency, cognitive tasks, and cognitive-motor assessments collected according to each study protocol.
-
Clinical and participant-reported outcomes
Clinical severity scales, functional assessments, symptoms, and participant reports that provide context for digital findings.
-
Video and guided assessments
Recordings of movement and ocular or oculomotor tasks, with assessment types selected for the condition and research question.
-
Selected biological measures
Biological measures analyzed alongside digital data in selected research, including the published FA analysis. Coverage is reviewed at the cohort level.
Research questions the data can support
Use relevant existing data to explore a focused scientific question and identify what additional evidence your program may need.
-
Candidate endpoint evaluation
Examine measure distributions, variability, and relationships with clinical assessments to help prioritize candidate endpoints.
-
Longitudinal change
Study within-person change and patterns over time in cohorts with repeated measurements and suitable follow-up.
-
Clinical relationships
Explore how digital measures relate to clinical severity, reported function, and selected biological measures where available.
-
Future study design
Use relevant recordings and assessment experience to inform measurement selection, study schedules, and follow-up needs.
Data access
Match the dataset to your program
Start with the population, measures, and question you want to investigate. BioSensics works with your team to identify relevant data and define the scope of access or analysis.
-
Step 1: Identify relevant cohorts
Review the indication, participant characteristics, study design, assessments, and available time points.
-
Step 2: Confirm coverage and permitted use
Assess data completeness, variable definitions, study permissions, and the requirements of the proposed research.
-
Step 3: Agree on the work and deliverables
Define an analysis plan or an agreed data transfer, with clear responsibilities, documentation, and outputs.
Connect the data with scientific support
Combine the database with BioSensics expertise in endpoint development, analysis, and interpretation when your program needs additional support.
-
Endpoint Development
Evaluate candidate endpoints using relevant existing data and design natural history studies to address the remaining evidence questions.
-
Data Analysis and Scientific Reporting
Prepare study data, define analysis methods, and communicate findings with clear scientific interpretation and documentation.
Bring relevant research data into your program
Talk with BioSensics about the cohorts, assessments, and analysis questions that fit your indication and development objectives.